Direct reporting cefazolin from VITEK 2 for E. coli, K. pneumoniae and P. mirabilis isolated from urine cultures using new CLSI interpretations

Abstract

Background: In recent years, Clinical and Laboratory Standard Institute (CLSI) has recommended a series breakpoint changes for cefazolin, including testing it as a surrogate agent for oral cephalosporins for treating uncomplicated urinary tract infections (uUTIs). Objectives: This study was conducted to evaluate the feasibility of direct reporting the cefazolin results from VITEK 2 for E. coli, K. pneumoniae, K. oxytoca and P. mirabilis isolated from patients with uUTIs using 2014 CLSI recommendation. Material and Methods: Cefazolin susceptibility results of urine cultures of the above four species generated from January 1, 2013 December 31, 2013, using both GN AST card N208 on VITEK 2 and cefazolin disk (gold standard) methods, were extracted from SoftMic Laboratory Information System and analyzed for their category agreement using 2014 CLSI interpretations. Results: Cefazolin susceptibilities of 1969 urinary isolates (1869 patients) of E. coli, K. pneumoniae/K. oxytoca and P. mirabilis comparing their VITEK 2 and disk test results, category agreement for cefazolin tested with both methods was 98%. The linear correlation between sensitive cefazolin and sensitive cephalothin MICs versus cefazolin zone diameters was good, with a predictive value of 99%. Conclusion: It is acceptable to report cefazolin directly from VITEK 2 for the named species from urine cultures. The susceptibility correlation among cefazolin, cephalothin and cefixime were excellent (excluded non-susceptible), further testing with individual oral cephalosporin agents, in this institute, may not be necessary. Recommendation: Final report accompanied by a comment in accordance with 2014 CLSI guideline is recommended to provide therapeutic guidance to clinicians.

Authors and Affiliations

Jianhui Xiong, Bradley Langford, Sigmund Krajden, Zafar Hussain, David Hancock, Mark Downing, William Chapman

Keywords

Related Articles

Swamp Fever in Horse: A Brief Overview

Swamp fever also known as equine infectious anemia is a viral disease of horses. The etiology belongs to the family Retroviridae and is transmitted by blood sucking insects and mosquitoes. Different strains of the virus...

Klebsiella: An insight into the virulence factors and antimicrobial susceptibility pattern

Introduction: Klebsiella pneumoniae is a frequent pathogen isolated from pneumonia, urinary tract infections, liver abscesses, wound infections, intravascular catheter infections, biliary tract infections, peritonitis an...

Incidental schistosomiasis in a case of carcinoma cervix

Although schistosomiasis usually involves the urinary tract however schistosomiasis of genital tract is infrequently encountered There has been strong evidences that schistosomiasis of the bladder predisposes to carcinom...

Evidence of potential threat of microbial drug resistance to commonly used antimicrobials in cases of active tubotympanic CSOM from Raipur, Chhattisgarh, India

Background: To identify the causative aerobic microbial pathogens of active tubotympanic (TT) type Chronic Suppurative Otitis Media (CSOM) and their antimicrobial susceptibility pattern. Method: A total of 248 clinically...

Penicillinase producing Neisseria gonorrhoeae (PPNG) and Tetracycline resistant Neisseria gonorrhoeae (TRNG) from Central Kerala

Gonorrhea is one of the oldest sexually transmitted disease, which has been mentioned in the Bible and ancient Chinese literature. As per WHO, the global incidence of gonorrhea is 106 million. The incidence of gonorrhea...

Download PDF file
  • EP ID EP242828
  • DOI -
  • Views 136
  • Downloads 0

How To Cite

Jianhui Xiong, Bradley Langford, Sigmund Krajden, Zafar Hussain, David Hancock, Mark Downing, William Chapman (2016). Direct reporting cefazolin from VITEK 2 for E. coli, K. pneumoniae and P. mirabilis isolated from urine cultures using new CLSI interpretations. IP International Journal of Medical Microbiology and Tropical Diseases, 2(2), 42-47. https://europub.co.uk/articles/-A-242828